Meet with us at this conference. Contact [email protected] to preschedule a meeting.
Hosted by the European Organization for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 30th EORTC-NCI-AACR Symposium will bring together academics, scientists and pharmaceutical industry representatives from across the globe to learn the latest innovations in drug development, target selection, and the impact of new discoveries in molecular biology.
The 2018 scientific program's highlights include:
- The latest preclinical and phase I studies data in targets and drugs
- Presentations of new drugs that will potentially change daily practice
- The latest on experimental models for cancer detection, diagnosis, and treatment
- Biomarker analysis for prediction and prognosis response
- Formulation of new drugs
- Immunotherapy and immunology
- Signal transduction and inhibition
- Molecular and cell biology
Charles River is pleased to be exhibiting in booth A2 at this event.
With a record of 55 patents, 17 clinical candidates and work on 80% of the oncology therapies approved in 2017, Charles River Discovery offers a comprehensive, integrated oncology portfolio with proven expertise to support drug development from hit ID to IND.
Utilizing the most effective combination of tools available to identify promising compounds, our broad range of models and support services allows clients to choose the most appropriate study design and screening method to identify most efficacious compounds and optimize lead candidates.
Moreover, our scientists can draw upon the wider Charles River organization to help progress your development candidate towards the clinic, thanks to an integrated approach to drug discovery.
Our team will be presenting the following posters:
- The in vivo screen: a format allowing the identification of sensitive PDX models | Nevisa Caushaj, Study Director, Charles River, Freiburg, Germany
- Characterization of tumor-infiltrating lymphocytes in a panel of patient-derived xenografts propagated in different humanized mouse models | Eva Oswald, Lab Head Innovative Models, Charles River, Freiburg, Germany
- Assessment of functional signal transduction pathway activity in patient-derived tumor xenografts to predict and evaluate therapy response | In collaboration with Philips Research - Laurent Holtzer, Senior Scientist at Philips Research, Eindhoven, The Netherlands
- Selection of suitable PDX models for the investigation of novel anti-cancer molecules using a comprehensive database | Hagen Klett, Bioinformatics Scientist, Charles River, Freiburg, Germany
- A translational platform using primary human immune cells in vitro, syngeneic and humanized models in vivo to support and advance immuno-oncology drug discovery | Omar Aziz, Director, Charles River, Harlow, United Kingdom
- Determination of ATP and inosine levels in tumor and tumor-free flank of PDX mice by freely moving in vivo microdialysis | Mariette Heins Study Director, Charles River, Groningen, Netherlands
- Translational imaging to monitor syngeneic oncological mouse models | Sabine Gorynia, Managing Director, Charles River, Freiburg, Germany
- Development of a disseminated AML mouose model to evaluate the therapeutic activity of immune checkpoint inhibitors using bioluminescence imaging | David Harris, Research Director, Charles River, North Carolina, USA
- Measurement of adenosine and metabolites in tumors of freely moving mice utilizing in vivo microdialysis | Mariette Heins, Study Director, Charles River, Groningen, Netherlands
Reprints of each poster are available at Charles River’s booth (#A2) during the conference, and our oncology experts would be happy to meet with those interested in discussing research and drug discovery.
Stop by our booth to learn more or contact us at [email protected] to preschedule a meeting.